| Pack Size | Single Vial, 10-Pack |
|---|
Tesamorelin + Ipamorelin Blend is a fixed-ratio research combination pairing 12 mg of Tesamorelin, a stabilised growth-hormone-releasing-hormone (GHRH) analogue, with 6 mg of Ipamorelin, a selective ghrelin-receptor agonist, in a single 18 mg lyophilized vial. The two compounds act on the growth-hormone axis through complementary receptors, which is why they are studied together. Every batch is independently third-party tested by HPLC for purity per component and mass spectrometry for identity, to a minimum of 99 percent purity. Supplied as a lyophilized powder for laboratory research use only.
Description
This blend combines two growth-hormone secretagogues that act on different receptors of the somatotroph. Tesamorelin is a stabilised analogue of GHRH(1-44) that engages the GHRH receptor; Ipamorelin is a selective agonist of the ghrelin receptor (GHSR-1a). Pairing a GHRH analogue with a ghrelin-receptor agonist is a common research design, because the two pathways converge on growth-hormone release through distinct mechanisms and are studied for their combined effect on the axis.
The vial is loaded at a 12 mg to 6 mg ratio (Tesamorelin to Ipamorelin), 18 mg of peptide total. It is provided strictly as a research-grade reagent for laboratory benchwork, and no content here concerns clinical use of either component.
Mechanism in research literature
Tesamorelin binds the GHRH receptor, a class-B G-protein-coupled receptor on anterior-pituitary somatotrophs, activating adenylate cyclase and driving synthesis and pulsatile release of growth hormone. Ipamorelin binds the ghrelin receptor (GHSR-1a) on the same cells, acting through a separate G-protein-coupled pathway that also promotes growth-hormone release and, notably, does so with high selectivity and minimal effect on cortisol or prolactin. Because the two receptors sit on the same cell but signal independently, the literature studies GHRH-analogue plus ghrelin-agonist combinations for their convergent action on growth-hormone secretion.
Both components preserve the pulsatile character of growth-hormone release and remain subject to physiological feedback, which distinguishes secretagogue research from the direct administration of growth hormone.
Studied properties
Documented areas of research for the two components include: GHRH-receptor pharmacology (Tesamorelin); selective ghrelin-receptor agonism with minimal cortisol and prolactin effect (Ipamorelin); pulsatile growth-hormone release; and the growth-hormone/IGF-1 axis. These describe the published research landscape and are provided for scientific context only. They are not claims of efficacy. Ronin Peptides supplies this blend exclusively as a research-grade reagent and provides no dosing protocols or therapeutic recommendations.
Compound specifications
| Product | Tesamorelin + Ipamorelin Blend |
|---|---|
| Components | Tesamorelin (GHRH analogue) + Ipamorelin (ghrelin-receptor agonist) |
| Content per vial | 12 mg Tesamorelin + 6 mg Ipamorelin (18 mg total) |
| Ratio | 2:1 (Tesamorelin:Ipamorelin) |
| Class | Dual growth-hormone secretagogue blend |
| Form | Lyophilized white-to-off-white powder |
| Solubility | Bacteriostatic water; sterile water for injection |
| Vial contents | 18 mg total peptide, sealed amber-glass vial under inert gas |
| Purity | ≥99% by HPLC per component (verified per batch by a third-party analytical lab) |
Storage and handling
Store unopened lyophilized vials dry and cold; long-term storage should be at or below −20 °C, protected from light and moisture. Once reconstituted, keep refrigerated at 2–8 °C and use within a few weeks; avoid repeated freeze–thaw cycles. Bring vials to room temperature before opening.
Compare with similar compounds
This blend pairs a GHRH analogue with a ghrelin-receptor agonist, the same complementary-pathway strategy used in the CJC-1295 + Ipamorelin blend; the distinction is that this product uses Tesamorelin, a stabilised GHRH(1-44) analogue, in place of CJC-1295. Researchers choosing between the two blends should anchor design to which GHRH analogue is the object of study, since the ghrelin-agonist component is shared. Either component is also available as a standalone single-compound vial for researchers studying one pathway in isolation.
Reconstitution and laboratory handling
An 18 mg blend vial reconstituted with 2 mL of bacteriostatic water yields 6 mg/mL of Tesamorelin and 3 mg/mL of Ipamorelin simultaneously — the two peptides share the same diluent volume at their 12 mg and 6 mg loadings. Other diluent volumes scale linearly: 3 mL gives 4 mg/mL Tesamorelin and 2 mg/mL Ipamorelin.
- Bring both vials to room temperature before opening.
- Sanitise both rubber stoppers with an alcohol swab.
- Pull the chosen diluent volume into a sterile transfer syringe.
- Direct the water against the inner wall of the peptide vial as it is injected — never onto the lyophilized cake.
- Invert slowly or swirl gently until dissolved. Do not vortex or shake.
- Refrigerate at 2–8 °C.
Frequently asked questions
What is in the Tesamorelin + Ipamorelin Blend?
A single vial contains 12 mg of Tesamorelin and 6 mg of Ipamorelin, 18 mg of peptide total, at a 2:1 ratio. Tesamorelin is a GHRH analogue and Ipamorelin is a ghrelin-receptor agonist.
Why combine the two peptides?
They act on the growth-hormone axis through different receptors on the same pituitary cell, so they are studied together for their complementary, convergent effect on growth-hormone release.
How does this differ from the CJC-1295 + Ipamorelin blend?
Both pair a GHRH analogue with Ipamorelin. This product uses Tesamorelin as the GHRH analogue instead of CJC-1295.
What is the regulatory status?
Supplied as a research-grade reagent for laboratory use only, not for human or veterinary use.
How do I receive the COA for my batch?
A certificate of analysis is available for your specific batch on request, tied to your lot.
References
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. The New England journal of medicine. 2007. PMID 18057338.
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology. 1998. PMID 9849822.
- Sinha DK et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology. 2020. PMID 32257855.
